Molecular targeting in childhood malignancies using nanoparticles

The goal of our project is to develop a new therapy for childhood malignancies using nanoformulated siRNA targeting Mxd3, a molecule in the Sonic Hedgehog signaling pathway, which we believe is important for cell survival. We plan to use cancer-specific ligands and superparamagnetic iron oxide nanoparticles (SPIO NPs) to carry siRNA. This delivery system will be tested in mouse xenograft models that we developed with primary cancer tissues. Our current focus is acute lymphoblastic leukemia (ALL), the most common cancer in children. We report our progress to date.

[1]  A. Zelenetz,et al.  Acute lymphoblastic leukemia. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  R. O’Donnell,et al.  Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD) , 2009, Investigational New Drugs.

[3]  Beverly L. Davidson,et al.  Current prospects for RNA interference-based therapies , 2011, Nature Reviews Genetics.

[4]  J. Tchinda,et al.  Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. , 2011, Blood.

[5]  M. Warmuth,et al.  Targeted Cancer Therapies in the Twenty‐First Century: Lessons From Imatinib , 2010, Clinical pharmacology and therapeutics.

[6]  L. Gore,et al.  Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development , 2010, British journal of haematology.

[7]  S. Bhatia.  Late effects among survivors of leukemia during childhood and adolescence. , 2003, Blood cells, molecules & diseases.

[8]  A. Hamilton,et al.  Targeted therapy in haematological malignancies , 2010, The Journal of pathology.

[9]  G. Pruneri,et al.  Human acute leukemia cells injected in NOD/LtSz‐scid/IL‐2Rγ null mice generate a faster and more efficient disease compared to other NOD/scid‐related strains , 2008, International journal of cancer.

[10]  J. Tuscano,et al.  Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non–Hodgkin's Lymphoma Xenograft Mouse Model , 2010, Clinical Cancer Research.

[11]  George A. Calin,et al.  RNA interference in the clinic: challenges and future directions , 2011, Nature Reviews Cancer.

[12]  Kit S. Lam,et al.  In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against α4β1 integrin , 2008, Molecular Cancer Therapeutics.

[13]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[14]  Claire Schwab,et al.  Acute lymphoblastic leukaemia. , 2011, Methods in molecular biology.

[15]  Kit S Lam,et al.  Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. , 2006, Nature chemical biology.

[16]  K. Lam,et al.  Maximization of loading and stability of ssDNA:iron oxide nanoparticle complexes formed through electrostatic interaction. , 2010, Langmuir : the ACS journal of surfaces and colloids.